Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Vertex Pharmaceuticals” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 159
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 159 pipeline programs matching "Vertex Pharmaceuticals" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

159 results for “Vertex Pharmaceuticals” Back to intelligence hub

Search results

Page 3 of 7
  1. VX22-445-123

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial
  2. VX24-AIS-D10

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial
  3. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial
  4. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial
  5. CTX001-121

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 2 small molecule active

    1 trial
  6. Cethrin

    Vertex Pharmaceuticals (Australia) Pty.

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial
  7. Inaxaplin

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 2 small molecule active

    1 trial
  8. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial
  9. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial
  10. Ivacaftor 25 mg/75 mg

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  11. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  12. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  13. P-1037

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  14. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial
  15. Placebo (matched to VX-121 suspension)

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  16. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial
  17. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial
  18. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial
  19. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial
  20. Telaprevir and Sofosbuvir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial
  21. Tezacaftor/Ivacaftor + Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  22. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial
  23. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  24. VCH-759 (BCH-27759)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.